Word

CSL SEQIRUS

Status

Pending

Status Code

688

Status Date

Tuesday, March 26, 2024

Serial Number

97542504

Mark Type

4000

Filing Date

Wednesday, August 10, 2022

Published for Opposition

Tuesday, January 30, 2024

Trademark Owner History

Seqirus UK Limited - Owner At Publication

Classifications

41 Education services including medical education services, namely, conducting classes, seminars, conferences, and workshops in the fields of pharmaceuticals, vaccines, biotechnology, biotherapy, immunology, rare diseases and blood conditions; health education, namely, providing classes in the field of health, vaccines, and immunology; consultancy services relating to education; provision of education services, namely, arranging and conducting of online conferences and symposia in the field of medical science via an online forum; provision of medical training and education courses in the field of health and medicine; publication of electronic educational materials; dissemination of printed and electronic educational material of others in the field of health and medicine; weblog services, namely, providing online non-downloadable blogs in the field of health and medicine; electronic publication of information on a wide range of topics, including online and over a global computer network, namely, electronic publishing of electronic publications featuring information on a wide range of topics

5 Pharmaceutical preparations and substances for the treatment and prevention of influenza, respiratory disease and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, stroke, and heart failure; pharmaceutical preparations and substances, namely, anti-virals and antibiotics; vaccines; blood products, namely, blood for medical purposes, blood plasma and cord blood for medical purposes; serums, namely, anti-venoms; medicated serums for the treatment of blood disorders and bleeding disorders; antibodies for use in the treatment of infectious diseases, cancer and autoimmune diseases; monoclonal and polyclonal antibodies for medical purposes; therapeutic monoclonal and polyclonal antibodies and antibodies for use in the treatment of infectious diseases; influenza vaccines; adjuvants for medical purposes and antigens being protein arrays for medical purposes; pharmaceutical preparations and substances for the treatment and prevention of blood or bleeding disorders; blood products, namely, blood plasma, reagent blood cells for medical use; products derived from blood and products derived from recombinant DNA technology, namely, blood substitutes being immunoglobulins, human albumin, blood clotting factors, plasma volume expanders, blood proteins for therapeutic human use; test kits, namely, invitro diagnostic reagent test kits comprised of medical diagnostic reagents for use in detecting cell mediated immune response; pharmaceutical preparations and substances, namely, RhD reagents for medical use for the detection of specific antigens and in blood typing; pharmaceutical preparations, namely, reagent red blood cells for medical purposes used to detect antibodies or IgG subtypes; pharmaceutical preparations, namely, monoclonal and polyclonal antibodies for pharmaceutical use; pharmaceutical preparations, namely, reagents for medical and clinical use for the typing and detection of specific blood cells, and the detection of relevant compliment components and immunoglobulin subtypes; diagnostic agents for medical purposes

1 Chemical and biological reagents for scientific purposes, research purposes, and non-medical purposes; cell culture reagents and media for scientific and research use; laboratory and scientific test kits for laboratory or research use, namely, reagent kits comprising generic DNA circle, DNA primers, polymerase and buffers for use in biotechnology fields; chemical preparations for scientific and industrial purposes; diagnostic and testing agents, namely, diagnostic reagents and diagnostic testing preparations for scientific and research use; chemical and biological reagents for non-medical purposes; chemical and biological reagents for industrial use for antibody screening, blood grouping, and for the typing and detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes all for non-medical purposes; chemical test kits for the detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes for laboratory or research use; chemical preparations for industrial use for anti-body screening, blood grouping, and the typing and detection of specific blood cells

44 Medical services; medical information services; health care services; health care information services; patient support services, namely, providing an internet-based database of patient medical information where patients can inquire about medical issues and procedures related to vaccination and immunology; providing medical information concerning blood products; providing medical information concerning vaccines, anti-venoms and immunohaematology products being diagnostic reagents; patient support services, namely, providing patient medical information where patients can enquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community via an Internet-based database

42 Scientific and technological services, namely, scientific research and product development in the field of vaccines; scientific research, analysis, and testing in the field of medicine, pharmaceuticals, vaccines, and biotechnology; research and development services, namely, scientific, medical, pharmaceutical and blood products research and development services; industrial analysis of biotechnology and immunology processes for product development in the field of pharmaceuticals and vaccines; providing medical research and scientific research information about the results of clinical trials for pharmaceuticals and vaccines; providing medical research and scientific research information in the field of clinical trials; provision of testing facilities for pharmaceutical research; laboratory analysis and research in the fields of pharmaceuticals, vaccines, bacteriology, and chemistry; management of scientific research projects; providing technical research in the field of pharmaceutical studies through preparation of technical studies, technical reports, scientific reports; providing technical research in the field of pharmaceutical studies through preparation of scientific and medical research projects, preparation of statistics and reports relating to scientific and medical research; provision of scientific research services and facilities, provision of scientific research results, information and outcomes in the field of health and medicine; provision of pharmaceutical research information relating to the aforementioned services; pharmaceutical research advisory and consultancy services relating to the aforementioned services; dissemination of pharmaceutical research and medical research information relating to the aforementioned services over a global computer network; medical laboratory services through scientific testing and screening services, namely, medical laboratory testing of human blood plasma for safety and quality; medical laboratory services regarding human blood plasma

Trademark Events

Mar 26, 2024

Noa E-Mailed - Sou Required From Applicant

Jan 30, 2024

Official Gazette Publication Confirmation E-Mailed

Jan 30, 2024

Published For Opposition

Jan 10, 2024

Notification Of Notice Of Publication E-Mailed

Dec 28, 2023

Approved For Pub - Principal Register

Dec 28, 2023

Examiner's Amendment Entered

Dec 28, 2023

Notification Of Examiners Amendment E-Mailed

Dec 28, 2023

Examiners Amendment E-Mailed

Dec 28, 2023

Examiners Amendment -Written

Dec 6, 2023

Teas/Email Correspondence Entered

Dec 5, 2023

Correspondence Received In Law Office

Dec 5, 2023

Teas Response To Office Action Received

Aug 15, 2023

Application Extension Granted/Receipt Provided

Aug 15, 2023

Application Extension To Response Period - Received

Jun 5, 2023

Notification Of Non-Final Action E-Mailed

Jun 5, 2023

Non-Final Action E-Mailed

Jun 5, 2023

Non-Final Action Written

May 30, 2023

Assigned To Examiner

Aug 30, 2022

New Application Office Supplied Data Entered

Aug 13, 2022

New Application Entered